Omnicell Unveils Strategy to Drive Autonomous Pharmacy Transformation and Expand Recurring Revenue

Reuters10-30

<a href="https://laohu8.com/S/OMCL">Omnicell</a> Unveils <a href="https://laohu8.com/S/MSTR">Strategy</a> to Drive Autonomous Pharmacy Transformation and Expand Recurring Revenue

Omnicell Inc. has released an investor presentation highlighting its position as a leader in medication management, with an installed base that includes more than half of the top 300 U.S. health systems. The company reported a robust product backlog of $647 million and annual recurring revenue of $580 million as of December 31, 2024. Omnicell outlined multiple growth drivers, including expanding its market presence and scaling recurring revenue through increased adoption of its products and solutions. The company's strategy focuses on transforming pharmacy care with robotics, smart devices, software workflows, expert services, and analytics to optimize clinical and business outcomes across various care settings. Additionally, Omnicell is investing in cloud-based, subscription-based services to support long-term customer value. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omnicell Inc. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579496117?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579496117","market":"fut","top_or_hot":-1,"title":"Omnicell Unveils Strategy to Drive Autonomous Pharmacy Transformation and Expand Recurring Revenue","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OMCL\">Omnicell</a> Unveils <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> to Drive Autonomous Pharmacy Transformation and Expand Recurring Revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Omnicell Inc. has released an investor presentation highlighting its position as a leader in medication management, with an installed base that includes more than half of the top 300 U.S. health systems. The company reported a robust product backlog of $647 million and annual recurring revenue of $580 million as of December 31, 2024. Omnicell outlined multiple growth drivers, including expanding its market presence and scaling recurring revenue through increased adoption of its products and solutions. The company's strategy focuses on transforming pharmacy care with robotics, smart devices, software workflows, expert services, and analytics to optimize clinical and business outcomes across various care settings. Additionally, Omnicell is investing in cloud-based, subscription-based services to support long-term customer value. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omnicell Inc. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Omnicell Unveils Strategy to Drive Autonomous Pharmacy Transformation and Expand Recurring Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOmnicell Unveils Strategy to Drive Autonomous Pharmacy Transformation and Expand Recurring Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-30 19:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OMCL\">Omnicell</a> Unveils <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> to Drive Autonomous Pharmacy Transformation and Expand Recurring Revenue\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Omnicell Inc. has released an investor presentation highlighting its position as a leader in medication management, with an installed base that includes more than half of the top 300 U.S. health systems. The company reported a robust product backlog of $647 million and annual recurring revenue of $580 million as of December 31, 2024. Omnicell outlined multiple growth drivers, including expanding its market presence and scaling recurring revenue through increased adoption of its products and solutions. The company's strategy focuses on transforming pharmacy care with robotics, smart devices, software workflows, expert services, and analytics to optimize clinical and business outcomes across various care settings. Additionally, Omnicell is investing in cloud-based, subscription-based services to support long-term customer value. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omnicell Inc. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OMCL","symbol_name":"Omnicell","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL5S4G8K:1","article_id":"2579496117","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579496117","pubTimestamp":1761822314,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Omnicell Inc. has released an investor presentation highlighting its position as a leader in medication management, with an installed base that includes more than half of the top 300 U.S. health systems. The company reported a robust product backlog of $647 million and annual recurring revenue of $580 million as of December 31, 2024. Omnicell outlined multiple growth drivers, including expanding its market presence and scaling recurring revenue through increased adoption of its products and solutions. The company's strategy focuses on transforming pharmacy care with robotics, smart devices, software workflows, expert services, and analytics to optimize clinical and business outcomes across various care settings. Additionally, Omnicell is investing in cloud-based, subscription-based services to support long-term customer value. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intellige","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OMCL":"Omnicell","BK4167":"医疗保健技术","BK4082":"医疗保健设备"},"translate_title":"Omnicell公布推动自主药房转型和扩大经常性收入的战略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMCL":0.9},"content_text":"Omnicell Unveils Strategy to Drive Autonomous Pharmacy Transformation and Expand Recurring Revenue\n    \n\n        Omnicell Inc. has released an investor presentation highlighting its position as a leader in medication management, with an installed base that includes more than half of the top 300 U.S. health systems. The company reported a robust product backlog of $647 million and annual recurring revenue of $580 million as of December 31, 2024. Omnicell outlined multiple growth drivers, including expanding its market presence and scaling recurring revenue through increased adoption of its products and solutions. The company's strategy focuses on transforming pharmacy care with robotics, smart devices, software workflows, expert services, and analytics to optimize clinical and business outcomes across various care settings. Additionally, Omnicell is investing in cloud-based, subscription-based services to support long-term customer value. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omnicell Inc. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579496117","isCrawlerRequest":true}